Global Alzheimer?s Disease Market, Forecast Till 2025

  • Category : Healthcare & Pharma
  • |
  • ID : 598425
  • |
  • Publishe Date : August 2018
  • |
  • No of Pages: 121
  • |
  • Publisher : Intellectual Research Partners

The Global Alzheimer?s Disease Market was valued at USD XX million in 2017, and is expected to grow at a CAGR of XX% by 2025. The market is growing by increase in prevalence of Alzheimer?s disease across the globe.

According to National Institute on Aging, Alzheimer?s disease is ranked as sixth leading cause of death among geriatric population in United States. Rising geriatric population and increasing incidences of neurodegenerative diseases are the two primary factors responsible for market growth. Research & Developments and technological advancements in products will provide numerous opportunity for market growth during the forecast period.

High cost treatment and lack of reimbursement are some of the factors that will affect the global Alzheimer?s disease Market negatively to certain extent.

The Marketed Drugs accounted for the largest market share in 2017 and is expected to grow considerably during the projected period. Easy availability from the manufacturers is one of the main factor for the segmental market growth.

Some of the key players operating in this market include Pfizer, Inc., Eisai Co., Ltd., Novartis AG, H. Lundbeck A/S, Forest Laboratories, Inc., TauRx Therapeutics Ltd, AC Immun, and Johnson & Johnson, and Others.

Key Benefits of the Report:
? Global, Regional, Country, Therapeutics, and Diagnostics Market Size and Forecast from 2014-2025
? Detailed market dynamics, industry outlook with market specific PESTLE, Value Chain, Supply Chain, and SWOT Analysis to better understand the market and build strategies
? Identification of key companies that can influence this market on a global and regional scale
? Expert interviews and their insights on market shift, current and future outlook and factors impacting vendors short term and long term strategies
? Detailed insights on emerging regions, Therapeutics & Diagnostics, and competitive landscape with qualitative and quantitative information and facts

Target Audience:
* Alzheimer?s disease treatment manufacturers
* Traders, Importer and Exporter
* Raw material suppliers and distributors
* Research and consulting firms
* Government and research organizations
* Associations and industry bodies

Research Methodology

The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective like analyst report of investment banks. The secondary research forms the base of our study where we conducted extensive data mining, referring to verified data sources such as white papers government and regulatory published materials, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factor, investment, market dynamics including technical scenario, consumer behavior, and end use industry trends and dynamics , capacity production, spending were taken into consideration.
We have assigned weights to these parameters and quantified their market impacts using the weighted average analysis to derive the expected market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs) which typically include:
? Original Equipment Manufacturer,
? Component Supplier,
? Distributors,
? Government Body & Associations, and
? Research Institute

TABLE OF CONTENT

1 EXECUTIVE SUMMARY

2 METHODOLOGY AND MARKET SCOPE
2.1 Research Methodology
2.2 Research Scope & Assumptions

3 ALZHEIMER?S DISEASE MARKET ? INDUSTRY OUTLOOK
3.1 Market Segmentation and Scope
3.2 Market Size & Growth Prospects
3.3 Alzheimer?s Disease Market ? Value Chain / Supply Chain Analysis
3.3.1 Company Landscape
3.4 Alzheimer?s Disease Market ? Market Dynamics
3.4.1 Market Driver
3.4.2 Market Restraints
3.4.3 Market Challenges
3.5 Alzheimer?s Disease Market Company Market Share, 2017
3.6 Alzheimer?s Disease Market ? Porter?s Five Forces Analysis
3.7 Alzheimer?s Disease Market ? Pestel Analysis

4 ALZHEIMER?S DISEASE MARKET THERAPEUTICS OUTLOOK
4.1 Alzheimer?s Disease Market Share by Therapeutics, 2016 & 2025
4.2 Marketed Drugs
4.3 Pipeline Drugs

5 ALZHEIMER?S DISEASE MARKET DIAGNOSTICS OUTLOOK
5.1 Alzheimer?s Disease Market Share by Diagnostics, 2016 & 2025
5.2 Lumbar puncture test
5.3 Computed tomography (CT) scan
5.4 Magnetic resonance imaging (MRI)
5.5 Others

6 ALZHEIMER?S DISEASE MARKET REGIONAL OUTLOOK
6.1 Alzheimer?s Disease Market Share by Region, 2016 & 2025
6.2 North America
6.2.1 North America Alzheimer?s Disease Market, 2014 - 2025
6.2.2 North America Alzheimer?s Disease Market, By Therapeutics, 2014 - 2025
6.2.3 North America Alzheimer?s Disease Market, By Diagnostics, 2014 - 2025
6.2.5 U.S.
6.2.5.1 U.S. Alzheimer?s Disease Market, By Therapeutics, 2014 - 2025
6.2.5.2 U.S. Alzheimer?s Disease Market, By Diagnostics, 2014 - 2025
6.2.6 Canada
6.2.6.1 Canada Alzheimer?s Disease Market, By Therapeutics, 2014 - 2025
6.2.6.2 Canada Alzheimer?s Disease Market, By Diagnostics, 2014 - 2025
6.3 Europe
6.3.1 Europe Alzheimer?s Disease Market, 2014 ? 2025
6.3.2 Europe Alzheimer?s Disease Market, By Therapeutics, 2014 - 2025
6.3.3 Europe Alzheimer?s Disease Market, By Diagnostics, 2014 - 2025
6.3.5 Germany
6.3.5.1 Germany Alzheimer?s Disease Market, By Therapeutics, 2014 - 2025
6.3.5.2 Germany Alzheimer?s Disease Market, By Diagnostics, 2014 - 2025
6.3.6 UK
6.3.6.1 UK Alzheimer?s Disease Market, By Therapeutics, 2014 - 2025
6.3.6.2 UK Alzheimer?s Disease Market, By Diagnostics, 2014 - 2025
6.4 Asia Pacific
6.4.1 Asia Pacific Alzheimer?s Disease Market, 2014 - 2025
6.4.2 Asia Pacific Alzheimer?s Disease Market, By Therapeutics, 2014 - 2025
6.4.3 Asia Pacific Alzheimer?s Disease Market, By Diagnostics, 2014 - 2025
6.4.5 Australia
6.4.5.1 Australia Alzheimer?s Disease Market, By Therapeutics, 2014 - 2025
6.4.5.2 Australia Alzheimer?s Disease Market, By Diagnostics, 2014 - 2025
6.4.6 New Zealand
6.4.6.1 New Zealand Alzheimer?s Disease Market, By Therapeutics, 2014 -
2025
6.4.6.2 New Zealand Alzheimer?s Disease Market, By Diagnostics, 2014 -2025
6.4.6.3 New Zealand Alzheimer?s Disease Market, By End-Use, 2014 -2025
6.4.7 China
6.4.7.1 China Alzheimer?s Disease Market, By Therapeutics, 2014 - 2025
6.4.7.2 China Alzheimer?s Disease Market, By Diagnostics, 2014 - 2025
6.4.8 India
6.4.8.1 India Alzheimer?s Disease Market, By Therapeutics, 2014 - 2025
6.4.8.2 India Alzheimer?s Disease Market, By Diagnostics, 2014 - 2025
6.4.9 Japan
6.4.9.1 Japan Alzheimer?s Disease Market, By Therapeutics, 2014 - 2025
6.4.9.2 Japan Alzheimer?s Disease Market, By Diagnostics, 2014 - 2025
6.5 South America
6.5.1 South America Alzheimer?s Disease Market, 2014 - 2025
6.5.2 South America Alzheimer?s Disease Market, By Therapeutics, 2014 - 2025
6.5.3 South America Alzheimer?s Disease Market, By Diagnostics, 2014 - 2025
6.5.5 Brazil
6.5.5.1 Brazil Alzheimer?s Disease Market, By Therapeutics, 2014 - 2025
6.5.5.2 Brazil Alzheimer?s Disease Market, By Diagnostics, 2014 - 2025
6.5.6 Mexico
6.5.6.1 Mexico Alzheimer?s Disease Market, By Therapeutics, 2014 - 2025
6.5.6.2 Mexico Alzheimer?s Disease Market, By Diagnostics, 2014 - 2025
6.6 MEA
6.6.1 MEA Alzheimer?s Disease Market, 2014 - 2025
6.6.2 MEA Alzheimer?s Disease Market, By Therapeutics, 2014 - 2025
6.6.3 MEA Alzheimer?s Disease Market, By Diagnostics, 2014 - 2025
7 COMPETITIVE LANDSCAPE
7.1 Pfizer, Inc
7.1.1 Company overview
7.1.2 Financial performance
7.1.3 Product benchmarking
7.1.4 Strategic initiatives
7.2 Eisai Co., Ltd
7.2.1 Company overview
7.2.2 Financial performance
7.2.3 Product benchmarking
7.2.4 Strategic initiatives
7.3 Novartis AG
7.3.1 Company overview
7.3.2 Financial performance
7.3.3 Product benchmarking
7.3.4 Strategic initiatives
7.4 H. Lundbeck A/S
7.4.1 Company overview
7.4.2 Financial performance
7.4.3 Product benchmarking
7.4.4 Strategic initiatives
7.5 Forest Laboratories, Inc
7.5.1 Company overview
7.5.2 Financial performance
7.5.3 Product benchmarking
7.5.4 Strategic initiatives
7.6 TauRx Therapeutics Ltd
7.6.1 Company overview
7.6.2 Financial performance
7.6.3 Product benchmarking
7.6.4 Strategic initiatives
7.7 AC Immun
7.7.1 Company overview
7.7.2 Financial performance
7.7.3 Product benchmarking
7.7.4 Strategic initiatives
7.8 Johnson & Johnson
7.8.1 Company overview
7.8.2 Financial performance
7.8.3 Product benchmarking
7.8.4 Strategic initiatives

End of the report
Disclaimer

Content are not available

Choose License Type